Today in Science Translational Medicine, researchers led by first author Joseph Castellano and corresponding author David Holtzman at Washington University, St. Louis, Missouri, publish extended findings of a study initially summarized on Alzforum after a symposium presentation (see ARF related news story). With other scientists at WashU, as well as collaborators at Weill Cornell Medical College of Cornell University, New York City; Lilly Research Labs in Indianapolis; and the Neuroscience Research Unit at Pfizer in Groton, Connecticut, the team reports a parallel series of human biomarker measurements and mouse brain interstitial fluid microdialysis studies. Together, the data suggest that ApoE variants contribute to a person’s risk for AD by way of affecting the peptide’s clearance from the brain long before amyloid deposition begins. Alzforum is hosting a Webinar discussion on this paper on 7 July 2011.—Gabrielle Strobel
- Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011 Jun 29;3(89):89ra57. PubMed.